Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| COLLEGIUM PHARMACEUTICAL, INCCOLL · Entity 5169 | Director | May 20, 2020 | May 22, 2020 |
| Molecular Templates, Inc.MTEM · Entity 85987 | Director | June 03, 2022 | June 06, 2022 |
| Poseida Therapeutics, Inc.PSTX · Entity 84243 | Director | July 23, 2021 | July 26, 2021 |
| RAPID MICRO BIOSYSTEMS, INC.RPID · Entity 6966 | Director | May 23, 2024 | May 28, 2024 |
| Tricida, Inc.TCDA · Entity 122050 | Director | June 15, 2022 | June 16, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
COLLEGIUM PHARMACEUTICAL, INC
Report date May 20, 2020 · Filed May 22, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 21,164 |
Reported balance
After 2020-05-20 transaction · row 1
1 source rowRow 1 · 2020-05-20 · Grant · Acquired 4,047 · Balance 21,164 F1: Reflects the grant of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. The restricted stock units vest on May 20, 2021, subject to the director's continued service with the issuer. The restricted stock units will be settled on such date, or, upon the election of the director, on the earlier of the end of the director's service on the Board of Directors, the director's death or disability, or a change in control of the issuer, in shares of the issuer's common stock. |
| Stock Option (Right to Purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $22.05 · Expires 2030-05-20 | Direct | 8,095 |
Reported balance
After 2020-05-20 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-05-20 · Grant · Acquired 8,095 · Balance 8,095 F2: The option vests and becomes exercisable on May 20, 2021, subject to the director's continued service with the issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the grant of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. The restricted stock units vest on May 20, 2021, subject to the director's continued service with the issuer. The restricted stock units will be settled on such date, or, upon the election of the director, on the earlier of the end of the director's service on the Board of Directors, the director's death or disability, or a change in control of the issuer, in shares of the issuer's common stock.
F2: The option vests and becomes exercisable on May 20, 2021, subject to the director's continued service with the issuer.
Molecular Templates, Inc.
Report date June 03, 2022 · Filed June 06, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.97 · Expires 2032-06-02 | Direct | 15,000 |
Reported balance
After 2022-06-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-06-03 · Grant · Acquired 15,000 · Balance 15,000 F1: 100% of the total number of shares subject to the option shall vest on June 3, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: 100% of the total number of shares subject to the option shall vest on June 3, 2023.
Poseida Therapeutics, Inc.
Report date July 23, 2021 · Filed July 26, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.63 · Expires 2031-07-23 | Direct | 25,833 |
Reported balance
After 2021-07-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-07-23 · Grant · Acquired 25,833 · Balance 25,833 F1: The stock option will vest and become exercisable on the earlier to occur of (i) June 16, 2022 and (ii) the day preceding the date of the 2022 annual meeting of the Issuer's stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option will vest and become exercisable on the earlier to occur of (i) June 16, 2022 and (ii) the day preceding the date of the 2022 annual meeting of the Issuer's stockholders.
RAPID MICRO BIOSYSTEMS, INC.
Report date May 23, 2024 · Filed May 28, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 14,300 |
Reported balance
After 2024-05-23 transaction · row 1
1 source rowRow 1 · 2024-05-23 · Grant · Acquired 14,300 · Balance 14,300 F1: Grant of restricted stock units ("RSUs") that vests in full on the earlier of (i) the first anniversary of the Grant Date, or (ii) the day immediately prior to the date of the next annual meeting of the stockholders of the Company provided that the Reporting Person remains in continuous service on such vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.82 · Expires 2034-05-22 | Direct | 28,650 |
Reported balance
After 2024-05-23 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-05-23 · Grant · Acquired 28,650 · Balance 28,650 F2: The option shall vest and become exercisable in full on the earlier of (i) the first anniversary of the Grant Date, or (ii) the day immediately prior to the date of the next annual meeting of the stockholders of the Company provided that the Reporting Person remains in continuous service on such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant of restricted stock units ("RSUs") that vests in full on the earlier of (i) the first anniversary of the Grant Date, or (ii) the day immediately prior to the date of the next annual meeting of the stockholders of the Company provided that the Reporting Person remains in continuous service on such vesting date.
F2: The option shall vest and become exercisable in full on the earlier of (i) the first anniversary of the Grant Date, or (ii) the day immediately prior to the date of the next annual meeting of the stockholders of the Company provided that the Reporting Person remains in continuous service on such vesting date.
Tricida, Inc.
Report date June 15, 2022 · Filed June 16, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.87 · Expires 2032-06-14 | Direct | 27,207 |
Reported balance
After 2022-06-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-06-15 · Grant · Acquired 27,207 · Balance 27,207 F1: Subject to the Reporting Person's continuous service to the Issuer as a non-employee director through each vesting date, this option vests ratably on a monthly basis, on the monthly anniversary of June 15, 2022 ("Option Date"), over the one-year period following the Option Date so that the option shall be 100% vested and exercisable on the one-year anniversary of the Option Date ("Vesting Date"); provided, however, if the Issuer's next regularly scheduled annual meeting of stockholders that occurs following the Option Date (the "Next Annual Meeting") occurs prior to the Vesting Date, then the option shall vest in full one day prior to the Next Annual Meeting. |
Filing footnotes · ownership attribution and instrument terms
F1: Subject to the Reporting Person's continuous service to the Issuer as a non-employee director through each vesting date, this option vests ratably on a monthly basis, on the monthly anniversary of June 15, 2022 ("Option Date"), over the one-year period following the Option Date so that the option shall be 100% vested and exercisable on the one-year anniversary of the Option Date ("Vesting Date"); provided, however, if the Issuer's next regularly scheduled annual meeting of stockholders that occurs following the Option Date (the "Next Annual Meeting") occurs prior to the Vesting Date, then the option shall vest in full one day prior to the Next Annual Meeting.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 23, 2024 Filed May 28, 2024 22:59 UTC | RAPID MICRO BIOSYSTEMS, INC. RPID · Entity 6966 | GrantStock Option (Right to Buy) · Derivative | 28,650 | $0.00 Strike: $0.82 | $0.00 |
DisclosureSEC source: 0001380106-24-000140 · wk-form4_1716937188.xml · derivative · entry 2 Hirsch David · CIK 0001619884 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,650 Underlying: Class A Common Stock · 28,650 shares Expires 2034-05-22 F2 · derivative.exercise_date: The option shall vest and become exercisable in full on the earlier of (i) the first anniversary of the Grant Date, or (ii) the day immediately prior to the date of the next annual meeting of the stockholders of the Company provided that the Reporting Person remains in continuous service on such vesting date. Read SEC document |
| May 23, 2024 Filed May 28, 2024 22:59 UTC | RAPID MICRO BIOSYSTEMS, INC. RPID · Entity 6966 | GrantClass A Common Stock | 14,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001380106-24-000140 · wk-form4_1716937188.xml · nonDerivative · entry 1 Hirsch David · CIK 0001619884 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,300 F1 · shares: Grant of restricted stock units ("RSUs") that vests in full on the earlier of (i) the first anniversary of the Grant Date, or (ii) the day immediately prior to the date of the next annual meeting of the stockholders of the Company provided that the Reporting Person remains in continuous service on such vesting date. Read SEC document |
| May 04, 2023 Filed May 5, 2023 22:01 UTC | RAPID MICRO BIOSYSTEMS, INC. RPID · Entity 6966 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $0.87 | $0.00 |
DisclosureSEC source: 0001380106-23-000079 · wf-form4_168332409394352.xml · derivative · entry 1 Hirsch David · CIK 0001619884 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Class A Common Stock · 25,000 shares Expires 2033-05-03 F1 · derivative.exercise_date: The option shall vest and become exercisable in full on the earlier of (i) the first anniversary of the Grant Date, or (ii) the day immediately prior to the date of the next annual meeting of the stockholders of the Company provided that the Reporting Person remains in continuous service on such vesting date. Read SEC document |
| June 15, 2022 Filed Jun 16, 2022 16:33 UTC | Tricida, Inc. TCDA · Entity 122050 | GrantStock Option (right to buy) · Derivative | 27,207 | $0.00 Strike: $9.87 | $0.00 |
DisclosureSEC source: 0001595585-22-000056 · wf-form4_165541157974491.xml · derivative · entry 1 Hirsch David · CIK 0001619884 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,207 Underlying: Common Stock · 27,207 shares Expires 2032-06-14 F1 · derivative.exercise_date: Subject to the Reporting Person's continuous service to the Issuer as a non-employee director through each vesting date, this option vests ratably on a monthly basis, on the monthly anniversary of June 15, 2022 ("Option Date"), over the one-year period following the Option Date so that the option shall be 100% vested and exercisable on the one-year anniversary of the Option Date ("Vesting Date"); provided, however, if the Issuer's next regularly scheduled annual meeting of stockholders that occurs following the Option Date (the "Next Annual Meeting") occurs prior to the Vesting Date, then the option shall vest in full one day prior to the Next Annual Meeting. Read SEC document |
| June 03, 2022 Filed Jun 6, 2022 07:30 UTC | Molecular Templates, Inc. MTEM · Entity 85987 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $0.97 | $0.00 |
DisclosureSEC source: 0000899243-22-021138 · doc4.xml · derivative · entry 1 Hirsch David · CIK 0001619884 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2032-06-02 F1 · derivative.exercise_date: 100% of the total number of shares subject to the option shall vest on June 3, 2023. Read SEC document |
| May 23, 2022 Filed Jun 10, 2022 22:30 UTC | RAPID MICRO BIOSYSTEMS, INC. RPID · Entity 6966 | GrantStock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $4.50 | $0.00 |
DisclosureSEC source: 0001127602-22-017266 · form4.xml · derivative · entry 1 Hirsch David · CIK 0001619884 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Class A Common Stock · 12,500 shares Expires 2032-05-22 F1 · derivative.exercise_date: The option shall vest and become exercisable in full on the earlier of (i) the first anniversary of the Grant Date, or (ii) the day immediately prior to the date of the next annual meeting of the stockholders of the Company provided that the Reporting Person remains in continuous service on such vesting date. Read SEC document |
| July 23, 2021 Filed Jul 26, 2021 20:30 UTC | Poseida Therapeutics, Inc. PSTX · Entity 84243 | GrantStock Option (Right to Buy) · Derivative | 25,833 | $0.00 Strike: $8.63 | $0.00 |
DisclosureSEC source: 0001209191-21-048256 · doc4.xml · derivative · entry 1 Hirsch David · CIK 0001619884 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,833 Underlying: Common Stock · 25,833 shares Expires 2031-07-23 F1 · derivative.exercise_date: The stock option will vest and become exercisable on the earlier to occur of (i) June 16, 2022 and (ii) the day preceding the date of the 2022 annual meeting of the Issuer's stockholders. Read SEC document |
| July 19, 2021 Filed Jul 21, 2021 00:15 UTC | RAPID MICRO BIOSYSTEMS, INC. RPID · Entity 6966 | ConversionCommon Stock Warrant · Derivative | 129,032 | Not disclosed Strike: $0.05 | Not disclosed |
DisclosureSEC source: 0001104659-21-094107 · tm2122156-19_4seq1.xml · derivative · entry 8 Hirsch David · CIK 0001619884 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · Held by Longitude Venture Partners II, L.P. Disclosed balance after: 129,032 Underlying: Class A Common Stock · 129,032 shares Expires 2028-01-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: The Issuer's Preferred Stock warrants automatically converted into warrants to purchase Common Stock immediately prior to the closing of the Issuer's initial public offering without payment or further consideration. The transaction is listed solely for the purpose of reporting the change in the shares underlying the warrants. F4 · derivative.exercise_date: Immediately exercisable. F2 · ownership.nature: The securities are held directly by Longitude Venture Partners II, L.P. ("LVP II"). Longitude Capital Partners II, LLC ("LCP II"), the general partner of LVP II, may be deemed to have voting and investment power with respect to the shares held by LVP II. The Reporting Person is a member of LCP II and may be deemed to share voting and investment power over the shares of the issuer held by LCP II. LCP II and Dr. Hirsch disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests therein. Read SEC document |
| July 19, 2021 Filed Jul 21, 2021 00:15 UTC | RAPID MICRO BIOSYSTEMS, INC. RPID · Entity 6966 | ConversionSeries B1 Warrant · Derivative | 645,160 | Not disclosed Strike: $0.01 | Not disclosed |
DisclosureSEC source: 0001104659-21-094107 · tm2122156-19_4seq1.xml · derivative · entry 7 Hirsch David · CIK 0001619884 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · Held by Longitude Venture Partners II, L.P. Disclosed balance after: 0 Underlying: Series B1 Preferred Stock · 645,160 shares Expires 2028-01-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: The Issuer's Preferred Stock warrants automatically converted into warrants to purchase Common Stock immediately prior to the closing of the Issuer's initial public offering without payment or further consideration. The transaction is listed solely for the purpose of reporting the change in the shares underlying the warrants. F3 · price: The Issuer's Preferred Stock warrants automatically converted into warrants to purchase Common Stock immediately prior to the closing of the Issuer's initial public offering without payment or further consideration. The transaction is listed solely for the purpose of reporting the change in the shares underlying the warrants. F3 · derivative.exercise_date: The Issuer's Preferred Stock warrants automatically converted into warrants to purchase Common Stock immediately prior to the closing of the Issuer's initial public offering without payment or further consideration. The transaction is listed solely for the purpose of reporting the change in the shares underlying the warrants. F2 · ownership.nature: The securities are held directly by Longitude Venture Partners II, L.P. ("LVP II"). Longitude Capital Partners II, LLC ("LCP II"), the general partner of LVP II, may be deemed to have voting and investment power with respect to the shares held by LVP II. The Reporting Person is a member of LCP II and may be deemed to share voting and investment power over the shares of the issuer held by LCP II. LCP II and Dr. Hirsch disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests therein. Read SEC document |
| July 19, 2021 Filed Jul 21, 2021 00:15 UTC | RAPID MICRO BIOSYSTEMS, INC. RPID · Entity 6966 | ConversionCommon Stock Warrant · Derivative | 500,000 | Not disclosed Strike: $0.05 | Not disclosed |
DisclosureSEC source: 0001104659-21-094107 · tm2122156-19_4seq1.xml · derivative · entry 6 Hirsch David · CIK 0001619884 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · Held by Longitude Venture Partners II, L.P. Disclosed balance after: 500,000 Underlying: Class A Common Stock · 500,000 shares Expires 2027-07-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: The Issuer's Preferred Stock warrants automatically converted into warrants to purchase Common Stock immediately prior to the closing of the Issuer's initial public offering without payment or further consideration. The transaction is listed solely for the purpose of reporting the change in the shares underlying the warrants. F4 · derivative.exercise_date: Immediately exercisable. F2 · ownership.nature: The securities are held directly by Longitude Venture Partners II, L.P. ("LVP II"). Longitude Capital Partners II, LLC ("LCP II"), the general partner of LVP II, may be deemed to have voting and investment power with respect to the shares held by LVP II. The Reporting Person is a member of LCP II and may be deemed to share voting and investment power over the shares of the issuer held by LCP II. LCP II and Dr. Hirsch disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests therein. Read SEC document |
| July 19, 2021 Filed Jul 21, 2021 00:15 UTC | RAPID MICRO BIOSYSTEMS, INC. RPID · Entity 6966 | ConversionSeries A1 Warrant · Derivative | 2,500,000 | Not disclosed Strike: $0.01 | Not disclosed |
DisclosureSEC source: 0001104659-21-094107 · tm2122156-19_4seq1.xml · derivative · entry 5 Hirsch David · CIK 0001619884 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · Held by Longitude Venture Partners II, L.P. Disclosed balance after: 0 Underlying: Series A1 Preferred Stock · 2,500,000 shares Expires 2027-07-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: The Issuer's Preferred Stock warrants automatically converted into warrants to purchase Common Stock immediately prior to the closing of the Issuer's initial public offering without payment or further consideration. The transaction is listed solely for the purpose of reporting the change in the shares underlying the warrants. F3 · price: The Issuer's Preferred Stock warrants automatically converted into warrants to purchase Common Stock immediately prior to the closing of the Issuer's initial public offering without payment or further consideration. The transaction is listed solely for the purpose of reporting the change in the shares underlying the warrants. F4 · derivative.exercise_date: Immediately exercisable. F2 · ownership.nature: The securities are held directly by Longitude Venture Partners II, L.P. ("LVP II"). Longitude Capital Partners II, LLC ("LCP II"), the general partner of LVP II, may be deemed to have voting and investment power with respect to the shares held by LVP II. The Reporting Person is a member of LCP II and may be deemed to share voting and investment power over the shares of the issuer held by LCP II. LCP II and Dr. Hirsch disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests therein. Read SEC document |
| July 19, 2021 Filed Jul 21, 2021 00:15 UTC | RAPID MICRO BIOSYSTEMS, INC. RPID · Entity 6966 | ConversionSeries C1 Preferred Stock · Derivative | 2,291,665 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-21-094107 · tm2122156-19_4seq1.xml · derivative · entry 4 Hirsch David · CIK 0001619884 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · Held by Longitude Venture Partners II, L.P. Disclosed balance after: 0 Underlying: Class A Common Stock · 458,333 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series A1 Preferred Stock, Series B1 Preferred Stock and Series C1 Preferred Stock (collectively, the "Preferred Stock") are convertible at any time, at the holder's election and have no expiration date. Each share of Preferred Stock automatically converted into 0.20 shares of the Issuer's Class A Common Stock upon the closing of the Issuer's initial public offering. F1 · price: The Series A1 Preferred Stock, Series B1 Preferred Stock and Series C1 Preferred Stock (collectively, the "Preferred Stock") are convertible at any time, at the holder's election and have no expiration date. Each share of Preferred Stock automatically converted into 0.20 shares of the Issuer's Class A Common Stock upon the closing of the Issuer's initial public offering. F1 · derivative.exercise_date: The Series A1 Preferred Stock, Series B1 Preferred Stock and Series C1 Preferred Stock (collectively, the "Preferred Stock") are convertible at any time, at the holder's election and have no expiration date. Each share of Preferred Stock automatically converted into 0.20 shares of the Issuer's Class A Common Stock upon the closing of the Issuer's initial public offering. F1 · derivative.expiration_date: The Series A1 Preferred Stock, Series B1 Preferred Stock and Series C1 Preferred Stock (collectively, the "Preferred Stock") are convertible at any time, at the holder's election and have no expiration date. Each share of Preferred Stock automatically converted into 0.20 shares of the Issuer's Class A Common Stock upon the closing of the Issuer's initial public offering. F2 · ownership.nature: The securities are held directly by Longitude Venture Partners II, L.P. ("LVP II"). Longitude Capital Partners II, LLC ("LCP II"), the general partner of LVP II, may be deemed to have voting and investment power with respect to the shares held by LVP II. The Reporting Person is a member of LCP II and may be deemed to share voting and investment power over the shares of the issuer held by LCP II. LCP II and Dr. Hirsch disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests therein. Read SEC document |
| July 19, 2021 Filed Jul 21, 2021 00:15 UTC | RAPID MICRO BIOSYSTEMS, INC. RPID · Entity 6966 | ConversionSeries B1 Preferred Stock · Derivative | 5,654,529 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-21-094107 · tm2122156-19_4seq1.xml · derivative · entry 3 Hirsch David · CIK 0001619884 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · Held by Longitude Venture Partners II, L.P. Disclosed balance after: 0 Underlying: Class A Common Stock · 1,130,904 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series A1 Preferred Stock, Series B1 Preferred Stock and Series C1 Preferred Stock (collectively, the "Preferred Stock") are convertible at any time, at the holder's election and have no expiration date. Each share of Preferred Stock automatically converted into 0.20 shares of the Issuer's Class A Common Stock upon the closing of the Issuer's initial public offering. F1 · price: The Series A1 Preferred Stock, Series B1 Preferred Stock and Series C1 Preferred Stock (collectively, the "Preferred Stock") are convertible at any time, at the holder's election and have no expiration date. Each share of Preferred Stock automatically converted into 0.20 shares of the Issuer's Class A Common Stock upon the closing of the Issuer's initial public offering. F1 · derivative.exercise_date: The Series A1 Preferred Stock, Series B1 Preferred Stock and Series C1 Preferred Stock (collectively, the "Preferred Stock") are convertible at any time, at the holder's election and have no expiration date. Each share of Preferred Stock automatically converted into 0.20 shares of the Issuer's Class A Common Stock upon the closing of the Issuer's initial public offering. F1 · derivative.expiration_date: The Series A1 Preferred Stock, Series B1 Preferred Stock and Series C1 Preferred Stock (collectively, the "Preferred Stock") are convertible at any time, at the holder's election and have no expiration date. Each share of Preferred Stock automatically converted into 0.20 shares of the Issuer's Class A Common Stock upon the closing of the Issuer's initial public offering. F2 · ownership.nature: The securities are held directly by Longitude Venture Partners II, L.P. ("LVP II"). Longitude Capital Partners II, LLC ("LCP II"), the general partner of LVP II, may be deemed to have voting and investment power with respect to the shares held by LVP II. The Reporting Person is a member of LCP II and may be deemed to share voting and investment power over the shares of the issuer held by LCP II. LCP II and Dr. Hirsch disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests therein. Read SEC document |
| July 19, 2021 Filed Jul 21, 2021 00:15 UTC | RAPID MICRO BIOSYSTEMS, INC. RPID · Entity 6966 | ConversionSeries A1 Preferred Stock · Derivative | 8,774,007 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-21-094107 · tm2122156-19_4seq1.xml · derivative · entry 2 Hirsch David · CIK 0001619884 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · Held by Longitude Venture Partners II, L.P. Disclosed balance after: 0 Underlying: Class A Common Stock · 1,754,801 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series A1 Preferred Stock, Series B1 Preferred Stock and Series C1 Preferred Stock (collectively, the "Preferred Stock") are convertible at any time, at the holder's election and have no expiration date. Each share of Preferred Stock automatically converted into 0.20 shares of the Issuer's Class A Common Stock upon the closing of the Issuer's initial public offering. F1 · price: The Series A1 Preferred Stock, Series B1 Preferred Stock and Series C1 Preferred Stock (collectively, the "Preferred Stock") are convertible at any time, at the holder's election and have no expiration date. Each share of Preferred Stock automatically converted into 0.20 shares of the Issuer's Class A Common Stock upon the closing of the Issuer's initial public offering. F1 · derivative.exercise_date: The Series A1 Preferred Stock, Series B1 Preferred Stock and Series C1 Preferred Stock (collectively, the "Preferred Stock") are convertible at any time, at the holder's election and have no expiration date. Each share of Preferred Stock automatically converted into 0.20 shares of the Issuer's Class A Common Stock upon the closing of the Issuer's initial public offering. F1 · derivative.expiration_date: The Series A1 Preferred Stock, Series B1 Preferred Stock and Series C1 Preferred Stock (collectively, the "Preferred Stock") are convertible at any time, at the holder's election and have no expiration date. Each share of Preferred Stock automatically converted into 0.20 shares of the Issuer's Class A Common Stock upon the closing of the Issuer's initial public offering. F2 · ownership.nature: The securities are held directly by Longitude Venture Partners II, L.P. ("LVP II"). Longitude Capital Partners II, LLC ("LCP II"), the general partner of LVP II, may be deemed to have voting and investment power with respect to the shares held by LVP II. The Reporting Person is a member of LCP II and may be deemed to share voting and investment power over the shares of the issuer held by LCP II. LCP II and Dr. Hirsch disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests therein. Read SEC document |
| July 19, 2021 Filed Jul 21, 2021 00:15 UTC | RAPID MICRO BIOSYSTEMS, INC. RPID · Entity 6966 | ConversionClass A Common Stock | 3,344,038 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-21-094107 · tm2122156-19_4seq1.xml · nonDerivative · entry 1 Hirsch David · CIK 0001619884 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · Held by Longitude Venture Partners II, L.P. Disclosed balance after: 3,407,952 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series A1 Preferred Stock, Series B1 Preferred Stock and Series C1 Preferred Stock (collectively, the "Preferred Stock") are convertible at any time, at the holder's election and have no expiration date. Each share of Preferred Stock automatically converted into 0.20 shares of the Issuer's Class A Common Stock upon the closing of the Issuer's initial public offering. F2 · ownership.nature: The securities are held directly by Longitude Venture Partners II, L.P. ("LVP II"). Longitude Capital Partners II, LLC ("LCP II"), the general partner of LVP II, may be deemed to have voting and investment power with respect to the shares held by LVP II. The Reporting Person is a member of LCP II and may be deemed to share voting and investment power over the shares of the issuer held by LCP II. LCP II and Dr. Hirsch disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests therein. Read SEC document |
| July 14, 2021 Filed Jul 16, 2021 00:00 UTC | RAPID MICRO BIOSYSTEMS, INC. RPID · Entity 6966 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $20.00 | $0.00 |
DisclosureSEC source: 0001104659-21-092758 · tm2122156-14_4seq1.xml · derivative · entry 1 Hirsch David · CIK 0001619884 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Class A Common Stock · 25,000 shares Expires 2031-07-13 F1 · derivative.exercise_date: This option vests and becomes exercisable, subject to the Reporting Person's continued service to the Issuer's Board, in 36 substantially equal monthly installments with the first installment vesting on August 14, 2021. Read SEC document |
| June 16, 2021 Filed Jun 17, 2021 17:03 UTC | Poseida Therapeutics, Inc. PSTX · Entity 84243 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $8.98 | $0.00 |
DisclosureSEC source: 0001209191-21-041511 · doc4.xml · derivative · entry 1 Hirsch David · CIK 0001619884 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2031-06-15 F1 · derivative.exercise_date: The stock option will vest and become fully exercisable on the earlier to occur of (i) June 16, 2022 and (ii) the day preceding the date of the next annual meeting of the stockholders of the Issuer. Read SEC document |
| June 10, 2021 Filed Jun 11, 2021 18:29 UTC | Tricida, Inc. TCDA · Entity 122050 | GrantStock Option (right to buy) · Derivative | 57,235 | $0.00 Strike: $4.92 | $0.00 |
DisclosureSEC source: 0001595585-21-000082 · wf-form4_162345057774060.xml · derivative · entry 3 Hirsch David · CIK 0001619884 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,235 Underlying: Common Stock · 57,235 shares Expires 2031-06-09 F3 · derivative.exercise_date: Subject to the Reporting Person's continuous service to the Issuer as a non-employee director through each vesting date, this option vests ratably on a monthly basis, on the monthly anniversary of June 10, 2021 ("Option Date"), over the one-year period following the Option Date so that the option shall be 100% vested and exercisable on the one-year anniversary of the Option Date ("Vesting Date"); provided, however, if the Next Annual Meeting occurs prior to the Vesting Date, then the option shall vest in full immediately prior to the Next Annual Meeting. Read SEC document |
| June 10, 2021 Filed Jun 11, 2021 18:29 UTC | Tricida, Inc. TCDA · Entity 122050 | GrantCommon Stock | 16,403 | $0.00 | $0.00 |
DisclosureSEC source: 0001595585-21-000082 · wf-form4_162345057774060.xml · nonDerivative · entry 1 Hirsch David · CIK 0001619884 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,584 F1 · shares: Represents restricted stock units ("RSUs") that vest on the earlier of (i) the one-year anniversary of June 10, 2021 (the "Grant Date") and (ii) the Issuer's next regularly scheduled annual meeting of stockholders that occurs following the Grant Date (the "Next Annual Meeting"), subject to the Reporting Person's continuous service as a non-employee director through such vesting date. Each RSU represents a contingent right to receive one share of Common Stock. Read SEC document |
| June 03, 2021 Filed Jun 4, 2021 16:30 UTC | Molecular Templates, Inc. MTEM · Entity 85987 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $8.98 | $0.00 |
DisclosureSEC source: 0000899243-21-022043 · doc4.xml · derivative · entry 1 Hirsch David · CIK 0001619884 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2031-06-03 F1 · derivative.exercise_date: 100% of the total number of shares subject to the option shall vest on June 3, 2022. Read SEC document |
| July 14, 2020 Filed Jul 15, 2020 17:00 UTC | Poseida Therapeutics, Inc. PSTX · Entity 84243 | ConversionSeries C Preferred Stock · Derivative | 491,159 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-042498 · doc4.xml · derivative · entry 4 Hirsch David · CIK 0001619884 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 393,872 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of the Issuer's Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into 0.8019246 shares of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F1 · price: Each share of the Issuer's Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into 0.8019246 shares of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of the Issuer's Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into 0.8019246 shares of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of the Issuer's Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into 0.8019246 shares of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F2 · ownership.nature: Represents shares held by Longitude Venture Partners III, L.P. ("LVP III"). Longitude Capital Partners III, LLC ("LCP III") is the general partner of LVP III and may be deemed to have voting, investment and dispositive power over securities held by LVP III. The reporting person is a member of LCP III and may be deemed to share voting, investment and dispositive power with respect to securities held by LVP III. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| July 14, 2020 Filed Jul 15, 2020 17:00 UTC | Poseida Therapeutics, Inc. PSTX · Entity 84243 | ConversionSeries B Preferred Stock · Derivative | 2,581,755 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-042498 · doc4.xml · derivative · entry 3 Hirsch David · CIK 0001619884 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 2,070,373 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of the Issuer's Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into 0.8019246 shares of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F1 · price: Each share of the Issuer's Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into 0.8019246 shares of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of the Issuer's Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into 0.8019246 shares of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of the Issuer's Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into 0.8019246 shares of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F2 · ownership.nature: Represents shares held by Longitude Venture Partners III, L.P. ("LVP III"). Longitude Capital Partners III, LLC ("LCP III") is the general partner of LVP III and may be deemed to have voting, investment and dispositive power over securities held by LVP III. The reporting person is a member of LCP III and may be deemed to share voting, investment and dispositive power with respect to securities held by LVP III. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| July 14, 2020 Filed Jul 15, 2020 17:00 UTC | Poseida Therapeutics, Inc. PSTX · Entity 84243 | PurchaseCommon Stock | 250,000 | $16.00 | $4,000,000.00 |
DisclosureSEC source: 0001209191-20-042498 · doc4.xml · nonDerivative · entry 2 Hirsch David · CIK 0001619884 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,714,245 F2 · ownership.nature: Represents shares held by Longitude Venture Partners III, L.P. ("LVP III"). Longitude Capital Partners III, LLC ("LCP III") is the general partner of LVP III and may be deemed to have voting, investment and dispositive power over securities held by LVP III. The reporting person is a member of LCP III and may be deemed to share voting, investment and dispositive power with respect to securities held by LVP III. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| July 14, 2020 Filed Jul 15, 2020 17:00 UTC | Poseida Therapeutics, Inc. PSTX · Entity 84243 | ConversionCommon Stock | 2,464,245 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-042498 · doc4.xml · nonDerivative · entry 1 Hirsch David · CIK 0001619884 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,464,245 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of the Issuer's Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into 0.8019246 shares of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F2 · ownership.nature: Represents shares held by Longitude Venture Partners III, L.P. ("LVP III"). Longitude Capital Partners III, LLC ("LCP III") is the general partner of LVP III and may be deemed to have voting, investment and dispositive power over securities held by LVP III. The reporting person is a member of LCP III and may be deemed to share voting, investment and dispositive power with respect to securities held by LVP III. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| July 09, 2020 Filed Jul 13, 2020 19:00 UTC | Poseida Therapeutics, Inc. PSTX · Entity 84243 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001209191-20-042313 · doc4.xml · derivative · entry 1 Hirsch David · CIK 0001619884 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2030-07-08 F1 · derivative.exercise_date: The stock option will vest and become exercisable in 12 equal monthly installments from the date of grant. Read SEC document |
| June 11, 2020 Filed Jun 15, 2020 21:58 UTC | Tricida, Inc. TCDA · Entity 122050 | GrantStock Option (right to buy) · Derivative | 22,967 | $0.00 Strike: $25.40 | $0.00 |
DisclosureSEC source: 0001628280-20-009469 · wf-form4_159227269916473.xml · derivative · entry 3 Hirsch David · CIK 0001619884 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,967 Underlying: Common Stock · 22,967 shares Expires 2030-06-10 F3 · derivative.exercise_date: Subject to the Reporting Person's continuous service to the Issuer as a non-employee director through each vesting date, this option vests ratably on a monthly basis, on the monthly anniversary of June 11, 2020 ("Option Date"), over the one-year period following the Option Date so that the option shall be 100% vested and exercisable on the one-year anniversary of the Option Date ("Vesting Date"); provided, however, if the Next Annual Meeting occurs prior to the Vesting Date, then the option shall vest in full immediately prior to the Next Annual Meeting. Read SEC document |
| June 11, 2020 Filed Jun 15, 2020 21:58 UTC | Tricida, Inc. TCDA · Entity 122050 | GrantCommon Stock | 5,670 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-20-009469 · wf-form4_159227269916473.xml · nonDerivative · entry 1 Hirsch David · CIK 0001619884 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,181 F1 · shares: Represents restricted stock units ("RSUs") that vest on the earlier of (i) the one-year anniversary of June 11, 2020 (the "Grant Date") and (ii) the Issuer's next regularly scheduled annual meeting of stockholders that occurs following the Grant Date (the "Next Annual Meeting"), subject to the Reporting Person's continuous service as a non-employee director through such vesting date. Each RSU represents a contingent right to receive one share of Common Stock. Read SEC document |
| May 28, 2020 Filed Jun 1, 2020 17:09 UTC | Molecular Templates, Inc. MTEM · Entity 85987 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $15.43 | $0.00 |
DisclosureSEC source: 0000899243-20-014739 · doc4.xml · derivative · entry 1 Hirsch David · CIK 0001619884 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2030-05-28 F1 · derivative.exercise_date: 100% of the total number of shares subject to the option shall vest on May 28, 2021. Read SEC document |
| May 26, 2020 Filed May 28, 2020 21:13 UTC | Molecular Templates, Inc. MTEM · Entity 85987 | OtherCommon Stock | 1,649 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-014484 · doc4.xml · nonDerivative · entry 2 Hirsch David · CIK 0001619884 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,649 F3 · kind: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by Longitude Capital III to its members. Read SEC document |
| May 26, 2020 Filed May 28, 2020 21:13 UTC | Molecular Templates, Inc. MTEM · Entity 85987 | OtherCommon Stock | 1,000,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-014484 · doc4.xml · nonDerivative · entry 1 Hirsch David · CIK 0001619884 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Longitude Venture Partners III, L.P. Disclosed balance after: 3,199,035 F1 · kind: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by Longitude Venture Partners III, L.P. ("Longitude Venture III") to its general and limited partners. F2 · ownership.nature: These shares are held by Longitude Venture III. The Reporting Person is a member of Longitude Capital Partners III, LLC ("Longitude Capital III"), the general partner of Longitude Venture III, and may be deemed to share voting, investment and dispositive power over these shares. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. Read SEC document |
| May 20, 2020 Filed May 22, 2020 20:24 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantStock Option (Right to Purchase) · Derivative | 8,095 | $0.00 Strike: $22.05 | $0.00 |
DisclosureSEC source: 0001192482-20-000366 · edgar.xml · derivative · entry 2 Hirsch David · CIK 0001619884 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,095 Underlying: Common Stock · 8,095 shares Expires 2030-05-20 F2 · derivative.exercise_date: The option vests and becomes exercisable on May 20, 2021, subject to the director's continued service with the issuer. Read SEC document |
| May 20, 2020 Filed May 22, 2020 20:24 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantCommon Stock | 4,047 | $0.00 | $0.00 |
DisclosureSEC source: 0001192482-20-000366 · edgar.xml · nonDerivative · entry 1 Hirsch David · CIK 0001619884 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,164 F1 · shares: Reflects the grant of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. The restricted stock units vest on May 20, 2021, subject to the director's continued service with the issuer. The restricted stock units will be settled on such date, or, upon the election of the director, on the earlier of the end of the director's service on the Board of Directors, the director's death or disability, or a change in control of the issuer, in shares of the issuer's common stock. Read SEC document |
| November 25, 2019 Filed Nov 27, 2019 16:43 UTC | Molecular Templates, Inc. MTEM · Entity 85987 | PurchaseCommon Stock | 937,000 | $8.00 | $7,496,000.00 |
DisclosureSEC source: 0000899243-19-028236 · doc4.xml · nonDerivative · entry 1 Hirsch David · CIK 0001619884 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Longitude Venture Partners III, L.P. Disclosed balance after: 4,198,535 F1 · shares: These shares were purchased pursuant to an underwritten public offering. F2 · ownership.direct: These shares are held by Longitude Venture Partners III, L.P. The Reporting Person is a member of Longitude Capital Partners III, LLC, the general partner of Longitude Venture Partners III, L.P., and may be deemed to share voting, investment and dispositive power over these shares. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. F2 · ownership.nature: These shares are held by Longitude Venture Partners III, L.P. The Reporting Person is a member of Longitude Capital Partners III, LLC, the general partner of Longitude Venture Partners III, L.P., and may be deemed to share voting, investment and dispositive power over these shares. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. Read SEC document |
| November 25, 2019 Filed Dec 5, 2019 16:16 UTC Amendment | Molecular Templates, Inc. MTEM · Entity 85987 | PurchaseCommon Stock | 937,500 | $8.00 | $7,500,000.00 |
DisclosureSEC source: 0000899243-19-028575 · doc4a.xml · nonDerivative · entry 1 Hirsch David · CIK 0001619884 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Longitude Venture Partners III, L.P. Disclosed balance after: 4,199,035 F1 · shares: These shares were purchased pursuant to an underwritten public offering. F2 · shares: Includes 500 shares that were inadvertently omitted from the original Form 4. F3 · ownership.direct: These shares are held by Longitude Venture Partners III, L.P. The Reporting Person is a member of Longitude Capital Partners III, LLC, the general partner of Longitude Venture Partners III, L.P., and may be deemed to share voting, investment and dispositive power over these shares. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. F3 · ownership.nature: These shares are held by Longitude Venture Partners III, L.P. The Reporting Person is a member of Longitude Capital Partners III, LLC, the general partner of Longitude Venture Partners III, L.P., and may be deemed to share voting, investment and dispositive power over these shares. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. Read SEC document |
| November 08, 2019 Filed Nov 13, 2019 21:33 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 25,000 | $19.33 | $483,250.00 |
DisclosureSEC source: 0001192482-19-000406 · edgar.xml · nonDerivative · entry 1 Hirsch David · CIK 0001619884 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,117 F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.00 to $19.66, inclusive. The reporting person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 29, 2019 Filed Sep 3, 2019 22:16 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Exercise / conversionStock Option (Right to Purchase) · Derivative | 19,853 | $0.00 Strike: $9.33 | $0.00 |
DisclosureSEC source: 0001192482-19-000352 · edgar.xml · derivative · entry 3 Hirsch David · CIK 0001619884 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 19,853 shares Expires 2027-05-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 29, 2019 Filed Sep 3, 2019 22:16 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 22,106 | $11.65 | $257,534.90 |
DisclosureSEC source: 0001192482-19-000352 · edgar.xml · nonDerivative · entry 2 Hirsch David · CIK 0001619884 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,117 F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.51 to $11.91, inclusive. The reporting person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 29, 2019 Filed Sep 3, 2019 22:16 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Exercise / conversionCommon Stock | 19,853 | $9.33 | $185,228.49 |
DisclosureSEC source: 0001192482-19-000352 · edgar.xml · nonDerivative · entry 1 Hirsch David · CIK 0001619884 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,223 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 31, 2019 Filed Jun 4, 2019 20:28 UTC | Tricida, Inc. TCDA · Entity 122050 | GrantStock Option (right to buy) · Derivative | 7,068 | $0.00 Strike: $36.74 | $0.00 |
DisclosureSEC source: 0001595585-19-000106 · wf-form4_155969450987208.xml · derivative · entry 3 Hirsch David · CIK 0001619884 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,068 Underlying: Common Stock · 7,068 shares Expires 2029-05-31 F3 · derivative.exercise_date: Subject to the Reporting Person's continuous service to the Issuer as a non-employee director through each vesting date, this option vests ratably on a monthly basis, on the monthly anniversary of May 31, 2019 ("Option Date"), over the one-year period following the Option Date so that the option shall be 100% vested and exercisable on the one-year anniversary of the Option Date ("Vesting Date"); provided, however, if the Next Annual Meeting occurs prior to the Vesting Date, then the option shall vest in full immediately prior to the Next Annual Meeting. Read SEC document |
| May 31, 2019 Filed Jun 4, 2019 20:28 UTC | Tricida, Inc. TCDA · Entity 122050 | GrantCommon Stock | 1,879 | $0.00 | $0.00 |
DisclosureSEC source: 0001595585-19-000106 · wf-form4_155969450987208.xml · nonDerivative · entry 1 Hirsch David · CIK 0001619884 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,511 F1 · shares: Represents restricted stock units ("RSUs") that vest on the earlier of (i) the one-year anniversary of May 31, 2019 (the "Grant Date") and (ii) the Issuer's next regularly scheduled annual meeting of stockholders that occurs following the Grant Date (the "Next Annual Meeting"), subject to the Reporting Person's continuous service as a non-employee director through such vesting date. Each RSU represents a contingent right to receive one share of Common Stock. Read SEC document |
| May 29, 2019 Filed May 30, 2019 19:55 UTC | Molecular Templates, Inc. MTEM · Entity 85987 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $8.21 | $0.00 |
DisclosureSEC source: 0000899243-19-015224 · doc4.xml · derivative · entry 1 Hirsch David · CIK 0001619884 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2029-05-29 F1 · derivative.exercise_date: 100% of the total number of shares subject to the option shall vest on May 29, 2020. Read SEC document |
| April 25, 2019 Filed Apr 29, 2019 22:50 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantStock Option (Right to Purchase) · Derivative | 9,414 | $0.00 Strike: $14.57 | $0.00 |
DisclosureSEC source: 0001192482-19-000218 · edgar.xml · derivative · entry 2 Hirsch David · CIK 0001619884 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,414 Underlying: Common Stock · 9,414 shares Expires 2029-04-25 F3 · derivative.exercise_date: The option vests and becomes exercisable on April 25, 2020, subject to the director's continued service with the issuer. Read SEC document |
| April 25, 2019 Filed Apr 29, 2019 22:50 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantCommon Stock | 4,707 | $0.00 | $0.00 |
DisclosureSEC source: 0001192482-19-000218 · edgar.xml · nonDerivative · entry 1 Hirsch David · CIK 0001619884 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,370 F1 · shares: Reflects the grant of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. The restricted stock units vest on April 25, 2020, subject to the director's continued service with the issuer. The restricted stock units will be settled on such date, or, upon the election of the director, on the earlier of the end of the director's service on the Board of Directors, the director's death or disability, or a change in control of the issuer, in shares of the issuer's common stock. F2 · balance_after: Includes 12,470 shares received in a distribution from Longitude Venture Partners, L.P. on August 14, 2018. Read SEC document |
| September 21, 2018 Filed Sep 25, 2018 16:18 UTC | Molecular Templates, Inc. MTEM · Entity 85987 | PurchaseCommon Stock | 365,000 | $5.50 | $2,007,500.00 |
DisclosureSEC source: 0001209191-18-052147 · doc4.xml · nonDerivative · entry 1 Hirsch David · CIK 0001619884 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Longitude Venture Partners III, L.P. Disclosed balance after: 3,261,535 F1 · ownership.direct: These shares are held by Longitude Venture Partners III, L.P. The Reporting Person is a member of Longitude Capital Partners III, LLC, the general partner of Longitude Venture Partners III, L.P., and may be deemed to share voting and investment power over these shares. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. F1 · ownership.nature: These shares are held by Longitude Venture Partners III, L.P. The Reporting Person is a member of Longitude Capital Partners III, LLC, the general partner of Longitude Venture Partners III, L.P., and may be deemed to share voting and investment power over these shares. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. Read SEC document |
| July 02, 2018 Filed Jul 2, 2018 21:13 UTC | Tricida, Inc. TCDA · Entity 122050 | GrantStock Option (right to buy) · Derivative | 13,147 | $0.00 Strike: $19.00 | $0.00 |
DisclosureSEC source: 0001140361-18-031067 · form4.xml · derivative · entry 7 Hirsch David · CIK 0001619884 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,147 Underlying: Common Stock · 13,147 shares Expires 2028-06-27 F4 · derivative.exercise_date: Subject to the Reporting Person's continuous service to the Issuer as a non-employee director through each vesting date, and subject to the Issuer's IPO closing on or before July 16, 2018, this option vests ratably on a monthly basis, on the monthly anniversary of June 27, 2018 ("Option Date"), over the one-year period following the Option Date so that the option shall be 100% vested and exercisable on the one-year anniversary of the Option Date ("Vesting Date"); provided, however, if the Next Annual Meeting occurs prior to the Vesting Date, then the option shall vest in full immediately prior to the Next Annual Meeting. Read SEC document |
| July 02, 2018 Filed Jul 2, 2018 21:13 UTC | Tricida, Inc. TCDA · Entity 122050 | ConversionSeries D Convertible Preferred Stock · Derivative | 1,817,447 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-18-031067 · form4.xml · derivative · entry 6 Hirsch David · CIK 0001619884 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Longitude Venture Partners II, L.P. Disclosed balance after: 0 Underlying: Common Stock · 456,644 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each of the Series C Convertible Preferred Stock and Series D Convertible Preferred Stock was convertible at any time at the option of the holder into Common Stock at a rate of 1/3.98, for no additional consideration, and had no expiration date. Each of the Series C Convertible Preferred Stock and Series D Convertible Preferred Stock automatically converted into Common Stock, at a rate of 1/3.98 and for no additional consideration, upon closing of the Issuer's initial public offering of its Common Stock. F1 · price: Each of the Series C Convertible Preferred Stock and Series D Convertible Preferred Stock was convertible at any time at the option of the holder into Common Stock at a rate of 1/3.98, for no additional consideration, and had no expiration date. Each of the Series C Convertible Preferred Stock and Series D Convertible Preferred Stock automatically converted into Common Stock, at a rate of 1/3.98 and for no additional consideration, upon closing of the Issuer's initial public offering of its Common Stock. F1 · derivative.exercise_date: Each of the Series C Convertible Preferred Stock and Series D Convertible Preferred Stock was convertible at any time at the option of the holder into Common Stock at a rate of 1/3.98, for no additional consideration, and had no expiration date. Each of the Series C Convertible Preferred Stock and Series D Convertible Preferred Stock automatically converted into Common Stock, at a rate of 1/3.98 and for no additional consideration, upon closing of the Issuer's initial public offering of its Common Stock. F1 · derivative.expiration_date: Each of the Series C Convertible Preferred Stock and Series D Convertible Preferred Stock was convertible at any time at the option of the holder into Common Stock at a rate of 1/3.98, for no additional consideration, and had no expiration date. Each of the Series C Convertible Preferred Stock and Series D Convertible Preferred Stock automatically converted into Common Stock, at a rate of 1/3.98 and for no additional consideration, upon closing of the Issuer's initial public offering of its Common Stock. F2 · ownership.direct: These shares are held directly by Longitude Venture Partners II, L.P. ("Longitude II"). Longitude Capital Partners II, LLC ("LCP2") is the general partner of Longitude II. The Reporting Person is a member of LCP2 and may be deemed to share voting and investment power over the shares of the Issuer held by Longitude II. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein, and this statement shall not be deemed an admission that the Reporting Person is a beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F2 · ownership.nature: These shares are held directly by Longitude Venture Partners II, L.P. ("Longitude II"). Longitude Capital Partners II, LLC ("LCP2") is the general partner of Longitude II. The Reporting Person is a member of LCP2 and may be deemed to share voting and investment power over the shares of the Issuer held by Longitude II. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein, and this statement shall not be deemed an admission that the Reporting Person is a beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| July 02, 2018 Filed Jul 2, 2018 21:13 UTC | Tricida, Inc. TCDA · Entity 122050 | ConversionSeries C Convertible Preferred Stock · Derivative | 9,677,419 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-18-031067 · form4.xml · derivative · entry 5 Hirsch David · CIK 0001619884 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Longitude Venture Partners II, L.P. Disclosed balance after: 0 Underlying: Common Stock · 2,431,511 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each of the Series C Convertible Preferred Stock and Series D Convertible Preferred Stock was convertible at any time at the option of the holder into Common Stock at a rate of 1/3.98, for no additional consideration, and had no expiration date. Each of the Series C Convertible Preferred Stock and Series D Convertible Preferred Stock automatically converted into Common Stock, at a rate of 1/3.98 and for no additional consideration, upon closing of the Issuer's initial public offering of its Common Stock. F1 · price: Each of the Series C Convertible Preferred Stock and Series D Convertible Preferred Stock was convertible at any time at the option of the holder into Common Stock at a rate of 1/3.98, for no additional consideration, and had no expiration date. Each of the Series C Convertible Preferred Stock and Series D Convertible Preferred Stock automatically converted into Common Stock, at a rate of 1/3.98 and for no additional consideration, upon closing of the Issuer's initial public offering of its Common Stock. F1 · derivative.exercise_date: Each of the Series C Convertible Preferred Stock and Series D Convertible Preferred Stock was convertible at any time at the option of the holder into Common Stock at a rate of 1/3.98, for no additional consideration, and had no expiration date. Each of the Series C Convertible Preferred Stock and Series D Convertible Preferred Stock automatically converted into Common Stock, at a rate of 1/3.98 and for no additional consideration, upon closing of the Issuer's initial public offering of its Common Stock. F1 · derivative.expiration_date: Each of the Series C Convertible Preferred Stock and Series D Convertible Preferred Stock was convertible at any time at the option of the holder into Common Stock at a rate of 1/3.98, for no additional consideration, and had no expiration date. Each of the Series C Convertible Preferred Stock and Series D Convertible Preferred Stock automatically converted into Common Stock, at a rate of 1/3.98 and for no additional consideration, upon closing of the Issuer's initial public offering of its Common Stock. F2 · ownership.direct: These shares are held directly by Longitude Venture Partners II, L.P. ("Longitude II"). Longitude Capital Partners II, LLC ("LCP2") is the general partner of Longitude II. The Reporting Person is a member of LCP2 and may be deemed to share voting and investment power over the shares of the Issuer held by Longitude II. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein, and this statement shall not be deemed an admission that the Reporting Person is a beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F2 · ownership.nature: These shares are held directly by Longitude Venture Partners II, L.P. ("Longitude II"). Longitude Capital Partners II, LLC ("LCP2") is the general partner of Longitude II. The Reporting Person is a member of LCP2 and may be deemed to share voting and investment power over the shares of the Issuer held by Longitude II. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein, and this statement shall not be deemed an admission that the Reporting Person is a beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| July 02, 2018 Filed Jul 2, 2018 21:13 UTC | Tricida, Inc. TCDA · Entity 122050 | GrantCommon Stock | 3,632 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-18-031067 · form4.xml · nonDerivative · entry 4 Hirsch David · CIK 0001619884 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,632 F3 · security: Represents restricted stock units ("RSUs") that, subject to the Issuer's initial public offering ("IPO") closing on or before July 16, 2018, vest on the earlier of (i) the one-year anniversary of June 27, 2018 (the "Grant Date") and (ii) the Issuer's next regularly scheduled annual meeting of stockholders that occurs following the Grant Date (the "Next Annual Meeting"), subject to the Reporting Person's continuous service as a non-employee director through such vesting date. Each RSU represents a contingent right to receive one share of Common Stock. F3 · shares: Represents restricted stock units ("RSUs") that, subject to the Issuer's initial public offering ("IPO") closing on or before July 16, 2018, vest on the earlier of (i) the one-year anniversary of June 27, 2018 (the "Grant Date") and (ii) the Issuer's next regularly scheduled annual meeting of stockholders that occurs following the Grant Date (the "Next Annual Meeting"), subject to the Reporting Person's continuous service as a non-employee director through such vesting date. Each RSU represents a contingent right to receive one share of Common Stock. Read SEC document |
| July 02, 2018 Filed Jul 2, 2018 21:13 UTC | Tricida, Inc. TCDA · Entity 122050 | PurchaseCommon Stock | 131,579 | $19.00 | $2,500,001.00 |
DisclosureSEC source: 0001140361-18-031067 · form4.xml · nonDerivative · entry 3 Hirsch David · CIK 0001619884 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Longitude Venture Partners II, L.P. Disclosed balance after: 3,019,734 F2 · ownership.direct: These shares are held directly by Longitude Venture Partners II, L.P. ("Longitude II"). Longitude Capital Partners II, LLC ("LCP2") is the general partner of Longitude II. The Reporting Person is a member of LCP2 and may be deemed to share voting and investment power over the shares of the Issuer held by Longitude II. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein, and this statement shall not be deemed an admission that the Reporting Person is a beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F2 · ownership.nature: These shares are held directly by Longitude Venture Partners II, L.P. ("Longitude II"). Longitude Capital Partners II, LLC ("LCP2") is the general partner of Longitude II. The Reporting Person is a member of LCP2 and may be deemed to share voting and investment power over the shares of the Issuer held by Longitude II. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein, and this statement shall not be deemed an admission that the Reporting Person is a beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| July 02, 2018 Filed Jul 2, 2018 21:13 UTC | Tricida, Inc. TCDA · Entity 122050 | ConversionCommon Stock | 456,644 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-18-031067 · form4.xml · nonDerivative · entry 2 Hirsch David · CIK 0001619884 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Longitude Venture Partners II, L.P. Disclosed balance after: 2,888,155 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each of the Series C Convertible Preferred Stock and Series D Convertible Preferred Stock was convertible at any time at the option of the holder into Common Stock at a rate of 1/3.98, for no additional consideration, and had no expiration date. Each of the Series C Convertible Preferred Stock and Series D Convertible Preferred Stock automatically converted into Common Stock, at a rate of 1/3.98 and for no additional consideration, upon closing of the Issuer's initial public offering of its Common Stock. F2 · ownership.direct: These shares are held directly by Longitude Venture Partners II, L.P. ("Longitude II"). Longitude Capital Partners II, LLC ("LCP2") is the general partner of Longitude II. The Reporting Person is a member of LCP2 and may be deemed to share voting and investment power over the shares of the Issuer held by Longitude II. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein, and this statement shall not be deemed an admission that the Reporting Person is a beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. F2 · ownership.nature: These shares are held directly by Longitude Venture Partners II, L.P. ("Longitude II"). Longitude Capital Partners II, LLC ("LCP2") is the general partner of Longitude II. The Reporting Person is a member of LCP2 and may be deemed to share voting and investment power over the shares of the Issuer held by Longitude II. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein, and this statement shall not be deemed an admission that the Reporting Person is a beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.